This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

11 Aug 2011

HP802-247 Therapy Shows Efficacy in Venous Leg Ulcers

HP802-247 achieved statistical significance, compared with control plus standard care, in both the primary and secondary endpoints.

Biopharmaceutical company Healthpoint Biotherapeutics has posted positive results from its Phase IIb trial of cell-based therapy HP802-247 in venous leg ulcers.


HP802-247 is an allogeneic living cell suspension that consists of a fibrinogen solution and a cell preparation containing a mixture of growth arrested, living, allogeneic epidermal keratinocytes and dermal fibroblasts.


The randomised, double blind, dose-finding study, which enrolled 228 subjects, is designed to determine the efficacy of two cell concentrations and two dosing frequencies of HP802-247, when combined with standard care, compared to control plus standard care over a 12-week treatment period.


Overall, HP802-247 achieve

Related News